Title: INCORPORATION OF THE B18R GENE TO ENHANCE ANTITUMOR EFFECT OF VIROTHERAPY

Abstract: The present invention relates to a novel composition and method to potentiate the antitumor effect of an oncolytic virus by providing for resistance against a host's innate interferon response. Particularly, a B18R gene is incorporated into an oncolytic virus. During treatment of a host with the modified oncolytic virus, the oncolytic virus retains its phenotype, and the host’s innate immune response has a minimal affect on viral replication.
A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 31/7088; A61K 35/76; C12N 7/01 (2012.01)
USPC - 424/93.2; 435/235.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. MINIMUM DOCUMENTATION SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

USPC - 424/93.2; 435/235.1

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y</td>
<td>Zamarin et al. Enhancement of oncolytic properties of recombinant Newcastle Disease Virus through antagonism of cellular innate immune responses. Molecular Therapy, 2009, vol 17(4), pp 696 - 706; Abstract, Figure 3a, (page 697, col 2, paras 2-5), (page 696, col 1, para 2), (page 696, col 2, para 2), (page 699, col 1, para 2 - page 702, col 2, para 1), (page 704, col 2, para 2)</td>
<td>1-34</td>
</tr>
<tr>
<td>Y</td>
<td>US 2008/0286237 A1 (KIRN) 20 November 2008 (20.1.2008); paras [0010], [0013], [0015]</td>
<td>4</td>
</tr>
<tr>
<td>Y</td>
<td>US 2006/0039894 A1 (MOHR et al.) 23 February 2006 (23.02.2006); Abstract</td>
<td>6, 17, 28</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C.

Special categories of cited documents:

- “A” document defining the general state of the art which is not considered to be of particular relevance
- “E” earlier application or patent but published on or after the international filing date
- “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- “O” document referring to an oral disclosure, use, exhibition or other means
- “P” document published prior to the international filing date but later than the priority date claimed

“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

“X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

“Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

“&” document member of the same patent family

Date of the actual completion of the international search

01 June 2012 (01.06.2012)

Date of mailing of the international search report

20 JUN 2012

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-1201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774